三个皮匠报告
最新
报告分类 研搜
热门标签
BETA
政策库
自研报告
new
入驻
搜索
当前位置：首页 >英文主页 >中英对照 > 中译版报告详情

艾意凯咨询&研发客：2025创新前行全球共进：中国临床试验发展的新篇章研究报告（中译版）（49页）.pdf

上传人： 1****1 编号：972105 2025-11-20 49页 1.42MB

下载：
打包下载报告合集

1、 2025 L.E.K.Consulting1These materials are intended to supplement a discussion with L.E.K.Consulting.These perspectives will,therefore,only be meaningful to those in attendance.The contents of the materials are confidential and subject to obligations of non-disclosure.Your attention is drawn to the

2、full disclaimer contained in this document.Advancing Innovation and Global Reach:The Next Chapter in Chinas Clinical Trial Development PharmaDJ x L.E.K.Clinical Development ReportNovember 2025 2025 L.E.K.Consulting2Foreword:This report summarizes the key strategic trends of clinical development in C

3、hina,and can be referenced by pharmaceutical companies and CROs to support their R&D/service strategies Over the past decade,Chinas clinical development landscape has undergone a remarkable transformation.The market has expanded rapidly,fueled by favorable policy reforms and sustained R&D investment

4、 from pharmas.This evolution has laid a strong foundation for the next phase of growth,one characterized by deeper innovation,greater global integration of Chinese biopharmas/biotechs and the increasing adoption of smarter tools such as artificial intelligence(AI).As the industry continues to mature

5、,China is poised to emerge as a leading hub globally for innovation-driven clinical development.This report,produced in collaboration with PharmaDJ,provides a comprehensive overview of the strategic trends shaping Chinas clinical trial ecosystem today.It highlights not only the progress made in inno

6、vation,globalization and AI/smarter clinical trial tools,but also the opportunities facing both multinational and Chinese companies.Supported by a comprehensive survey of pharmaceutical companies and contract research organizations(CROs),this report serves as a starting point for multinational corpo

word格式文档无特别注明外均可编辑修改，预览文件经过压缩，下载原文更清晰！
三个皮匠报告文库所有资源均是客户上传分享，仅供网友学习交流，未经上传用户书面授权，请勿作商用。
根据《Advancing Innovation and GlobalReach: The Next Chapter in China’sClinical Trial Development》报告，中国临床试验发展呈现以下关键点： 1. 中国临床试验市场快速增长，2024年临床试验数量约为美国和欧洲的0.8倍和1.1倍。 2. 中国生物制药和生物技术公司加大创新药物研发投入，推动临床试验从早期到晚期的发展。 3. 中国创新药物全球化趋势明显，中国生物制药和生物技术公司积极开展海外临床试验和许可交易。 4. 人工智能在临床试验中的应用潜力巨大，有望提高效率和质量。 5. 中国临床试验行业面临同质化竞争，企业需通过差异化策略应对。 6. 中国临床试验行业未来发展趋势包括：开发更多创新和差异化疗法、中国创新全球化、采用人工智能和更智能的临床试验工具。
未来趋势揭秘" 效率革命即将到来？" 全球化之路如何走？"
全行业研究报告分享下载平台
  • 0731-84720580
  • 商务合作：really158d
  • 友链申请 (QQ)：1737380874
关于我们
更多
关于我们
三个皮匠报告微信公众号
三个皮匠报告微信小程序
扫码咨询商务合作事宜
友情链接：
营销自动化 亿欧智库 微播易 阿里妈妈
copyright@2008-2013 长沙思想领动信息技术有限公司版权所有        网站备案/许可证号：湘B2-20190120 | 工信部备案号：湘ICP备2023027541号-2 | 公安备案号：湘公网安备43010402001071号
客服
商务合作
小程序
服务号
折叠